2025-09-08 New Indication of Grand Pharma’s Globally Innovative Radioactive Product SIR-Spheres® Y-90 Resin Microsphere Injection Is Officially Approved in Europe

2025-09-04 2025 Interim Results Conference and Investor Open Day Review

2025-07-31 Grand Pharma has entered into a deep strategic partnership with the Belgian Institut National des Radioéléments

2025-07-23 The Application for Grand Pharma’s Global Innovative RDC TLX591 to Join an International Multicenter Phase III Clinical Trial Obtains Implied Approval From the NMPA

2025-07-18 The World’s First Nasal Spray Product of Grand Pharma for the Treatment of Dry Eye Disease, OC-01, Achieves the First Batch of Commercial Prescriptions After Its Official Approval in Mainland China

2025-07-08 A New Indication of Grand Phamra’s Globally Innovative Radioactive Product SIR-Spheres® Y-90 Resin Microsphere Injection Is Officially Approved by the FDA Ahead of Schedule

2025-06-05 Grand Pharma’s Global Innovative Ophthalmic Drug CBT-001 Completes the Enrollment of All Patients in the International Multi-Center Phase III Clinical Trial

2025-05-30 Grand Pharma’s Global Innovative Product for the Treatment of Demodex Blepharitis Is Approved for Commercialization by Macao ISAF of China

2025-03-01 Update on Strategic Investment in Telix

2025-04-22 The Clinical Study in China of the Global Innovative RDC GPN02006 Achieved a Milestone Breakthrough

2025-05-06 2024 Grand Pharma Annual Report

2025-05-07 The Phase II Clinical Study in China of the Global Innovative Product STC3141 Successfully Reached the Clinical Endpoint